# Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis

> **NCT07187895** · PHASE2 · TERMINATED · sponsor: **Sinotau Pharmaceutical Group** · enrollment: 17 (actual)

## Conditions studied

- Myocardial Perfusion Imaging
- Diagnostic Certainty
- Stable Coronary Artery Disease

## Interventions

- **DRUG:** XTR004

## Key facts

- **NCT ID:** NCT07187895
- **Lead sponsor:** Sinotau Pharmaceutical Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-12-19
- **Primary completion:** 2025-03-05
- **Final completion:** 2025-03-05
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** The main objective of this study has been achieved. Following internal discussions, the sponsor has decided to terminate this study early.
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07187895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07187895, "Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07187895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*